微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 12.94% | 105.07% | 38.99% | 13/159 | 1.2% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | 9.31% | 335.05% | 86.2% | 10/159 | 0.26% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | 5% | 170.27% | -1.96% | 11/159 | -0.37% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | 5.1% | -27.76% | -19.18% | 58/159 | -9.52% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | 6.31% | 51.32% | 194.86% | 58/159 | 4.23% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 2.14% | 92.79% | 15.68% | 78/159 | 2.66% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 1.85% | 10.12% | -73.8% | 64/159 | 2.32% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 7.06% | 0.28% | 69.3% | 48/159 | -1.03% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 4.17% | -15.07% | 275.68% | 78/159 | 2.34% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 1.11% | -41.27% | -33.93% | 101/159 | 1.46% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 1.68% | -6.67% | -76.14% | 68/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 7.04% | -23.06% | 43.38% | 55/159 | 0.67% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 4.91% | -33.11% | 159.79% | 64/159 | 2.8% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 1.89% | -58.73% | 5% | 88/159 | 2.16% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 1.8% | -32.33% | -80.33% | 65/159 | 1.57% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 9.15% | -27.95% | 24.66% | 44/159 | 0.75% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 7.34% | 2% | 60.26% | 58/159 | 4.43% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 4.58% | -38.61% | 72.18% | 61/159 | 2.94% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 2.66% | 2% | -79.06% | 50/159 | 2.49% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 12.7% | 9.11% | 70.24% | 39/159 | 3.58% | 哈三联 | 27.17% | 行业排名> |
| 2020-06-30 | 7.46% | 2% | -35.91% | 31/159 | 4.19% | 汇宇制药 | 55.94% | 行业排名> |
| 2019-12-31 | 11.64% | 32.57% | 32.57% | 47/159 | 2.53% | 河化股份 | 45.32% | 行业排名> |
| 2018-12-31 | 8.78% | -27.26% | -27.26% | 58/159 | 6.99% | 汇宇制药 | 31.9% | 行业排名> |
| 2017-12-31 | 12.07% | 2% | 2% | 37/159 | 9.61% | 誉衡药业 | 35.56% | 行业排名> |